Recent Updates
Recently added Catalysts

Arvinas, Inc.

ARVNFDA catalysts, PDUFA dates & pipeline intelligence
$6.82
▲ +0.05 · +0.74%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ARVN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $6.3352W HIGH $14.51
Volume
1.53 M
Value Traded
10.17 M
Short % Float
9.8%
Days to Cover
7.6
-1.3%Week
-6.06%1 Month
-29.55%3 Month
-25.05%6 Month
-86.43%5 Year
-56.71%All Time

Cash Data

Unlock ARVN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
446.61 M
EPS (TTM)
-0.15
P/E Ratio
-
Ent. Value
-111.19 M
Total Shares
65.49 M
Float Shares
58.68 M
Insiders
10.38%
Institutions
85.19%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1 data presentation
ARV-393 (zaloblideg)
relapsed/refractory non-Hodgkin lymphoma (NHL)
Phase 1Small MoleculesOncology
Unlock every ARVN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ARVN Catalyst Timeline

Dated clinical, regulatory and corporate events for Arvinas, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Arvinas, Inc.

574Total events
25Upcoming
124Tier-1 (high impact)
2018 to 2028Coverage

Upcoming catalysts 2

T2R&D Day
Subscribe to view catalyst details
T3Poster Presentation
Subscribe to view catalyst details
ARV-393

Event history 50

●AbstractARV-393Presentation
Full ASH abstract for ARV-393 Phase 1 study available via ASH online program
relapsed/refractory non-Hodgkin lymphomasource ↗
●Quarterly UpdateCorporate
Reported third quarter 2026 financial results and corporate update
▲Late-BreakerARV-102Presentation
Late-breaking oral presentation of Phase 1 ARV-102 oculomotor and biomarker data at MDS 2026
Parkinson's diseasesource ↗
▲Biomarker DataARV-102Clinical Data
CSF LRRK2 reductions correlated with oculomotor and synaptic biomarker changes
Parkinson's diseasesource ↗
▲Oral PresentationARV-102Presentation
Late-breaking oral presentation of Phase 1 ARV-102 oculomotor and biomarker data at MDS 2026
Parkinson's diseasesource ↗
▲Poster PresentationARV-102Presentation
E-Poster presentation of Phase 1 oculomotor and biomarker data for ARV-102 at MDS 2026
Parkinson's diseasesource ↗
▲Full ResultsARV-102Clinical Data
Final Phase 1 data for ARV-102 in Parkinson's disease presented
Parkinson's diseasesource ↗
◆Poster PresentationARV-102Presentation
E-poster presentation of Phase 1 ARV-102 oculomotor and biomarker data at 2026 MDS Congress
Parkinson's diseasesource ↗
▲Poster PresentationARV-102Presentation
E-Poster presentation of Phase 1 ARV-102 oculomotor and biomarker data at MDS 2026
Parkinson's diseasesource ↗
◆Biomarker DataARV-102Clinical Data
Novel biomarker data from Phase 1 trial of ARV-102 in Parkinson's disease to be presented
Parkinson's diseasesource ↗
Unlock the full ARVN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ARVN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-04ARV-6723 Pre-clinical data presentation Pre-clinical
Unlock 14 more ARVN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 18%
Micro Cap
(rank 131 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Sep 2026)
Showing 7 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ARV-6723 Small MoleculesNCT07749586Advanced Solid TumorPhase 1/2 RECRUITING 499Mar 31, 2032
ARV-393 Small MoleculesNCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Phase 1 RECRUITING 329Mar 1, 2028
ARV-110 Small MoleculesCompletedNCT03888612Prostate Cancer MetastaticPhase 1/2 COMPLETED 248Jan 27, 2025
Bavdegalutamide Small MoleculesCompletedNCT05177042Prostate Cancer MetastaticPhase 1 COMPLETED 45Apr 10, 2025
ARV-806 Gene TherapiesNCT07023731KRAS G12D MutationPhase 1/2 COMPLETED 76Oct 30, 2026
ARV-471 in combination with Everolimus Small MoleculesMarketedNCT05501769Breast CancerApproved COMPLETED 184Aug 25, 2025
Vepdegestrant Small MoleculesMarketedNCT04072952Breast CancerApproved COMPLETED 219Mar 5, 2026
Unlock the ARVN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ARVN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
ARV-102 Parkinson's diseasePhase 12026-03-18greater than 50% LRRK2 degradation in the CSF; approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14; maintained the reduction through day 28Read MoreArvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 DaysRead More
Scroll for more · summaries link to the source press release
Unlock every ARVN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ARVN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Loomis David KOfficer (VP, Chief Accounting Officer)Sell -232 39,961 held$6.36 11/09/2026
Unlock the full ARVN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
AFFINITY ASSET ADVISORS, LLC 0.6 % (-62.5 %) 15.86 M 2.05 M 225.4% ( 1.42 M)
Unlock every fund holding ARVN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ARVN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ARVN ownership
Insider and institutional ownership, quarter by quarter.

ARVN Short Interest

Shares sold short, counted twice a month.

9.8%
Short % of Float
of tradable shares sold short
5.8M
Shares Sold Short
+2.8% vs prior count
7.6 High
Days to Cover
trading days of normal volume to buy every short share back
757.5K
Avg Daily Volume
the average used for days to cover
Unlock ARVN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ARVN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ARVN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ARVN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ARVN ranks across every disease it competes in

Competitive Position is a premium feature
See how ARVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ARVN News

ARVN
Nov 11, 2026
ARVNConferences/Events

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas, Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18. The company is known for its innovative protein degradation therapies and has multiple investigational drugs in clinical trials. Arvinas recently achieved FDA approval for its first PROTAC drug, developed in partnership with Pfizer.

Read more →
ARVN
Nov 4, 2026
ARVNConferences/Events
▼ -11.7%on this news

Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting

Arvinas announced that preliminary clinical data for ARV-393 (zaloblideg) will be presented at the 2026 ASH Annual Meeting. The data will cover safety, pharmacokinetics, and preliminary efficacy in patients with relapsed/refractory non-Hodgkin lymphoma. ARV-393 specifically targets the BCL6 protein, implicated in various lymphomas.

Read more →
ARVN
Nov 3, 2026
ARVNGeneral
▼ -5.7%on this newsshared move

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Arvinas reported its third quarter 2026 financial results, highlighting the initiation of dosing in a Phase 1/2 trial of ARV-6723. The company reaffirmed its commitment to share clinical data from several ongoing trials in late 2026 and 2027. Additionally, ARV-102 showed promising results in Parkinson's disease during a recent conference presentation.

Read more →
ARVN
Oct 27, 2026
ARVNGeneral

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation

Arvinas has reinstated the Early Career Researcher Award to honor innovative research in targeted protein degradation. The award, which includes a $25,000 prize, aims to support emerging scientists and will accept nominations from November 1 to December 31, 2026. The winner will be recognized in mid-2027.

Read more →
ARVN
Oct 27, 2026
ARVNGeneral

Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

Arvinas, Inc. will report its third quarter 2026 financial results on November 3, 2026. The live webcast will begin at 8:00 a.m. ET, accessible via the investor page on their website. The company is known for its innovative protein degradation therapies and has several investigational drugs in clinical development.

Read more →
ARVN
Oct 7, 2026
ARVNPhases

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Arvinas, Inc. presented promising data from a Phase 1 clinical trial of ARV-102 for Parkinson's disease, showing improvements in eye movement and biomarker correlations. The trial indicated that ARV-102 effectively targets LRRK2, relevant to neurodegenerative diseases. The findings support further clinical evaluation of ARV-102, despite the study not being designed to assess clinical efficacy.

Read more →
ARVN
Oct 1, 2026
ARVNConferences/Events

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas, Inc. announced that it will present novel biomarker data from its Phase 1 clinical trial of ARV-102 at the 2026 International Congress of Parkinson's Disease and Movement Disorders. The investigational drug targets LRRK2, a protein implicated in Parkinson's disease. Presentations will occur both as oral and e-poster sessions during the congress in Seoul, Korea.

Read more →
ARVN
Sep 29, 2026
ARVNGeneral

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arvinas, Inc. has announced the granting of stock options and restricted stock units to a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term with an exercise price matching the stock's closing price on the grant date. Arvinas continues to develop innovative therapies through its PROTAC platform, targeting various diseases.

Read more →
ARVN
Sep 28, 2026
ARVNPhases

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas, Inc. has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral PROTAC targeting HPK1 in advanced solid tumors. This marks Arvinas' first entry into immuno-oncology. Preclinical studies showed promising results, indicating ARV-6723's potential to enhance immune activity and address resistance to existing therapies. The trial will evaluate safety and preliminary antitumor activity.

Read more →
ARVN
Sep 3, 2026
ARVNConferences/Events

Arvinas to Participate in Upcoming Investor Conferences

Arvinas, Inc. announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference. The company is focused on developing therapies using its PROTAC platform, which targets disease-causing proteins. Arvinas is advancing multiple investigational drugs for various conditions, highlighting its commitment to innovation in biotechnology.

Read more →
ARVN
Aug 4, 2026
ARVNFDA Updates
▲ +11.7%on this news

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arvinas, Inc. reported strong financial results for Q2 2026, highlighted by the FDA's approval of VEPPANU, the first PROTAC therapy. The company has successfully licensed VEPPANU to Rigel Pharmaceuticals and anticipates sharing clinical data from three Phase 1 programs within the next year. Additionally, promising preclinical data was presented for the HPK1 degrader program, ARV-6723.

Read more →
ARVN
Jul 28, 2026
ARVNGeneral

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Arvinas, Inc. will report its second quarter 2026 financial results on August 4, 2026, during a live webcast. The event will include a corporate update and can be accessed via the company's investor page. Arvinas is known for its innovative PROTAC platform, which targets disease-causing proteins for degradation.

Read more →
ARVN
Jun 4, 2026
ARVNPhases

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas, Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) and the Parkinson’s Precision Medicine Initiative (PPMI), programs supported by The Michael J. Fox Foundation. This collaboration aims to advance ARV-102, Arvinas’ investigational treatment targeting LRRK2 for conditions like Parkinson's disease. The initiatives will focus on enhancing understanding of LRRK2 biology and accelerating the development of targeted therapies. Arvinas has a commitment to improving treatments for neurodegenerative diseases through innovative research.

Read more →
ARVN
Jun 1, 2026
ARVNConferences/Events

Arvinas to Present at Jefferies Global Healthcare Conference 2026

Arvinas, Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for its innovative drug development using targeted protein degradation. They have successfully developed the first FDA-approved PROTAC for treating advanced breast cancer and are advancing multiple investigational drugs for various diseases.

Read more →
ARVN
May 18, 2026
ARVNGeneral

Arvinas Employees Give Back During Company-wide Impact Day

Arvinas, a clinical-stage biotechnology company, celebrated its fourth Company-wide Impact Day, where employees engaged in various community service activities across multiple locations. The company emphasizes its commitment to both patients and the communities where it operates. This year's initiatives included preparing meals for patients, creating comforting blankets, and beautifying local spaces. The event demonstrates Arvinas' dedication to making a positive impact. CEO Randy Teel expressed pride in the employees' passion for community service.

Read more →
ARVN
May 12, 2026
ARVNGeneral

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas and Pfizer have entered into a license agreement with Rigel Pharmaceuticals for the exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC therapy for certain types of breast cancer. The agreement includes an initial payment of $85 million, with opportunities for additional payments based on development milestones. Rigel will handle commercialization in the U.S., while Arvinas and Pfizer will continue their development efforts. The transaction is subject to necessary regulatory approvals, which could delay the implementation of their plans.

Read more →
ARVN
May 12, 2026
ARVNFDA Updates

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas, Inc. reported its first quarter 2026 financial results and corporate updates, highlighting significant developments including the FDA approval of VEPPANU, a groundbreaking PROTAC for advanced breast cancer. The approval marks a milestone as it is the first of its kind, correlating with Arvinas' long-term focus on targeted protein degradation. Additionally, Phase 1 clinical trials show encouraging results for other drug candidates like ARV-102 for Parkinson's disease. Arvinas is also expanding collaborations and planning further trials, reinforcing its growth trajectory in the biotechnology sector.

Read more →
ARVN
May 5, 2026
ARVNConferences/Events

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas, Inc. will report its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The live webcast will begin at 8:00 a.m. ET and will be accessible on the company's investor page. Arvinas is known for its innovative protein degradation therapies and has made significant advancements in treating various cancers and neurodegenerative disorders.

Read more →

About Arvinas, Inc.

New Haven, CT 246 employees arvinas.com
Headquarters395 WINCHESTER AVE, NEW HAVEN, CT, 06511
Founded2013
BIOPHARMAWATCH ELITE
Trade the next ARVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime